HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 386 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.45 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8 | -72.4% | 211 | -73.9% | 0.00% | – |
| Q2 2023 | $29 | +383.3% | 807 | +366.5% | 0.00% | – |
| Q1 2023 | $6 | -97.7% | 173 | -96.2% | 0.00% | -100.0% |
| Q4 2022 | $262 | -95.6% | 4,591 | +3133.1% | 0.00% | – |
| Q3 2022 | $6,000 | -53.8% | 142 | -57.0% | 0.00% | – |
| Q4 2021 | $13,000 | 0.0% | 330 | 0.0% | 0.00% | – |
| Q3 2021 | $13,000 | -13.3% | 330 | 0.0% | 0.00% | – |
| Q2 2021 | $15,000 | -53.1% | 330 | -56.6% | 0.00% | – |
| Q1 2021 | $32,000 | -15.8% | 760 | -15.6% | 0.00% | – |
| Q4 2020 | $38,000 | +11.8% | 900 | -30.8% | 0.00% | – |
| Q3 2020 | $34,000 | -37.0% | 1,300 | -35.0% | 0.00% | – |
| Q2 2020 | $54,000 | -85.6% | 2,000 | -89.6% | 0.00% | -100.0% |
| Q1 2018 | $376,000 | -3.1% | 19,172 | 0.0% | 0.00% | -50.0% |
| Q4 2017 | $388,000 | – | 19,172 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 14,092,771 | $256,066,000 | 16.64% |
| BB BIOTECH AG | 8,247,860 | $149,864,000 | 3.97% |
| MSD Partners, L.P. | 2,245,000 | $40,792,000 | 3.07% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 428,633 | $5,969,000 | 2.84% |
| First Light Asset Management, LLC | 885,523 | $16,090,000 | 2.60% |
| SNYDER CAPITAL MANAGEMENT L P | 2,387,350 | $43,378,000 | 1.93% |
| Sterling Global Strategies LLC | 22,000 | $400,000 | 1.74% |
| Taylor Wealth Management Partners | 221,380 | $4,022,000 | 1.71% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,228,399 | $167,680,000 | 1.68% |
| DOHENY ASSET MANAGEMENT /CA | 124,393 | $2,260,000 | 1.18% |